GUIDELINES®
RECOMMENDED
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend avapritinib (AYVAKIT) (if platelets ≥50 x 109/L) as an NCCN Category 2A, preferred first-line treatment option for advanced systemic mastocytosis (SM), including aggressive SM (ASM), SM with an associated hematologic neoplasm (SM-AHN) (when the SM component requires prioritization over the AHN component), and mast cell leukemia (MCL).2*
*NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
NCCN=National Comprehensive Cancer Network.
The ONLY treatment to selectively target the underlying mutation1
Avapritinib is a tyrosine kinase inhibitor designed for the potent and selective inhibition of KIT D816V—the underlying driver of disease in ~95% of cases.2,4-6
References: 1. Data on file. Blueprint Medicines Corporation, Cambridge, MA. 2. AYVAKIT [prescribing information]. Cambridge, MA: Blueprint Medicines Corporation; November 2024. 3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Systemic Mastocytosis V.1.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed February 21, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 4. Kristensen T et al. Am J Hematol. 2014;89(5):493-498. 5. Garcia-Montero AC et al. Blood. 2006;108(7):2366-2372. 6. Ungerstedt J et al. Cancers. 2022;14(16):3942.